Cell / tissue culture

#Academic #Analysis #Automation / robotics #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Chemical engineering #Chemistry #Drug development #Drug discovery #Drug targets #Flow Cytometry #Gene therapy #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Molecular medicine #Nanomedicine / nanotechnology #Oncology #Precision medicine #Regulatory #RNA #Sequencing #Stem cells #System biology #Therapeutics

Unlocking the potential of Extracellular Vesicles: from single molecules to novel therapeutics

Unlocking the potential of Extracellular Vesicles: from single molecules to novel therapeutics By Dr Anna Caballe and Dr Katarzyna Ginda-Makela As part of normal homeostasis, cells release different types of small-sized membrane vesicles to traffic analytes across membranes, communicate with other cells and remove unwanted cell content. These vesicles can… Read More

#Archive #Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Biologics / Biotechnology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug repositioning #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Immunology / Virology & Vaccines #In Silico Biology #Lead discovery #Microbiome #Molecular medicine #Nanomedicine / nanotechnology #Oncology #Patent Law #Precision medicine #Protein chemistry / Proteomics #Regenerative Medicine #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

2030 Life Sciences and Health in the Digital Age (Part 2)

By Dr Steve Arlington and John Wise As part of its mission to help members anticipate and prepare for changes in the pharmaceutical industry, The Pistoia Alliance has developed a research paper which sets out to consider what the life science, biopharma R&D and healthcare ecosystem might look like in… Read More

#Exclusive Content

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Enabling technologies #High Content Screening #High throughput screening #Imaging #Lead discovery #Molecular medicine #Oncology #Pharmacology #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology

Using Live-Cell Imaging Systems to Transform Perspectives in Drug Discovery

Using Live-Cell Imaging Systems to Transform Perspectives in Drug Discovery By Helen Stewart-Miller and Dr Kate Tointon Live-cell imaging has transformed the study of cell behaviour and function. The technique allows researchers to monitor internal cell structures, interactions and processes in real-time, and over time. In drug discovery, understanding the… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Medicinal chemistry #Microfluidics #Molecular medicine #Pathology #Pharmacology #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Toxicology

Optimising Phenotypic Screening – Single-cell analysis versus 3D multicell analysis

Optimising Phenotypic Screening - Single-cell analysis versus 3D multicell analysis By Dr Richard M. Eglen In light of the high failure rate of compounds when they are subjected to clinical testing, we are seeing a renaissance in phenotypic screening in drug discovery. However, most phenotypic screening is based on the… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #High Content Screening #High throughput screening #Imaging #Lead discovery #Microbiome #Oncology #Pharmokinetics #Preclinical #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

Evolving Models for NASH Drug Discovery: Tools for stemming a silent epidemic

Evolving Models for NASH Drug Discovery: Tools for stemming a silent epidemic By Dr Sue Grepper, Dr Radina Kostadinova, Dr Eva Thoma and Professor Armin Wolf Non-alcoholic fatty liver disease (NAFLD) has quietly become one of the most common causes of chronic liver disease in the modern world. If this… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biologics / Biotechnology #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Immunology #In Silico Biology #Lead discovery #Lead optimisation #Molecular medicine #Oncology #Orphan drugs #Pathology #Pharmacology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation

Fail Early, Fail Fast – A phenotypic rescue approach

Fail Early, Fail Fast - A phenotypic rescue approach By Dr Anne-Marie Zuurmond, et al. New disease targets frequently emerge in literature, but the thorough target validation required to consider these targets for a drug discovery programme is often lacking. In pharmacological or genetic perturbation studies using complex biological assays,… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Business #Cell / tissue culture #Cell culture #Cellular assays #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Lead discovery #Oncology #Precision medicine #Protein chemistry / Proteomics #Screening #Stem cells #System biology #Systems biology #Toxicology

Automated Cell-based Assays: Novel tools overcome the barriers to discovery success

Automated Cell-based Assays: Novel tools overcome the barriers to drug discovery success By Helen Stewart-Miller and Kate Tointon In this article, we look at how commercial products and services are facilitating the automation of cell-based assays to advance drug discovery and accelerate the delivery of new medicines to patients. Cell-based… Read More

#Archive

#AI / data analytics / healthtech / informatics #Biologics / Biotechnology #Business #Cell / tissue culture #Cell culture #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Gene editing #Gene therapy #Genomics #Lead discovery #Oncology #Pharmacology #Regenerative Medicine #Regulatory #Screening #Stem cells #System biology #Systems biology #Therapeutics

Cell Therapy – Falling short of its potential?

Cell Therapy - Falling short of its potential? By Pierre-Louis Joffrin Despite major investment in the field, few cell therapies have gained regulatory approval with limited commercial success. The success of therapeutic products is defined by three factors: safety, efficacy and scalability. Achieving these for cell therapy presents new challenges;… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biochemistry #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Molecular medicine #Oncology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

From Genotype to Phenotype: Leveraging functional genomics in oncology

From Genotype to Phenotype: Leveraging functional genomics in oncology By Dr Menelas Pangalos & Steve Rees et al. A challenge in drug discovery is that, at best, only around one in five drug candidates will lead to the launch of a medicine. In 2011, AstraZeneca initiated a strategic ‘5R Framework’… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Flow Cytometry #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Lead optimisation #Oncology #PCR #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology #Translational #Translational chemistry

3D Organoid Cell Culture: Optimising disease models for drug discovery

3D Organoid Cell Culture - Optimising disease models for research and drug discovery By Dr Amanda Linkous, Hilary Sherman, Iris Li and Dr Richard M. Eglen The use of human-induced pluripotent stem cells (HiPSCs) continues to grow in three-dimensional (3D) spheroid and organoid culture. Although advances in 3D cell culture… Read More

#Archive

Organoids
#Academic #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Pathology #Pharmacology #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics

The Growth of Organoids in Cancer Drug Discovery

The Growth of Organoids in Cancer Drug Discovery By Dr J. Mark Treherne, et al., Will the automated expansion of organoids help improve the productivity of cancer drug discovery? Increasingly, complex cell-based assays and tissues are routinely used as part of cancer drug discovery. However, conventional monolayer or suspension cultures… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #High throughput screening #Imaging #Lead discovery #Lead optimisation #Molecular medicine #Oncology #Organic chemistry #Pathology #Pharmacology #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Stem cells #Target validation #Therapeutics #Toxicology

Increasing Drug Discovery Success With 3D Cell Culture Systems

Increasing Drug Discovery Success With 3D Cell Culture Systems By Dr Richard M. Eglen, Dr Feng Li and Dr Tony Frutos Drug candidates often fail in the clinic for two reasons: they lack efficacy or possess an adverse toxicity profile. These failures can come at a high cost, especially when… Read More

#Archive

Scientist in laboratory
#Analysis #Business #Cell / tissue culture #Cell culture #Clinical specialities #Clinical trials #Drug development #Drug discovery #Regulatory #RNA #Screening #Toxicology

Good Laboratory Practice – To GLP or not to GLP?

By Scott Hickman, Dr Brian Ogilvie and Tim Patterson. Good Laboratory Practice (GLP), are federal regulations that require implementation of a robust quality management system to ensure the validity, integrity and reliability of non-clinical safety data submitted for regulatory evaluation and approval. US Food and Drug Administration (FDA) GLP regulations… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Bioengineering #Biologics / Biotechnology #Biomarkers #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Clinical specialities #Clinical trials #Drug development #Drug discovery #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Lead optimisation #Microfluidics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology #Translational #Translational chemistry

3D Cell Culture – Engineering Composable, Disease-Tunable 3D Human Microtissues for Drug Discovery

3D Cell Culture - Engineering Composable, Disease-Tunable 3D Human Microtissues for Drug Discovery By Dr Patrick Guye, Dr Eva Thoma and Dr Olivier Frey In this article, we will share some of what we have learned over the past 10 years as pioneers in the 3D cell culture space and… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Animal models #Automation / robotics #Biochemistry #Bioengineering #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Genetics #High Content Screening #High throughput screening #Imaging #In Silico Biology #Lead discovery #Mass spectrometry / NMR #Medicinal chemistry #Molecular medicine #Oncology #Organic chemistry #Pathology #PCR #Pharmacology #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology #Translational #Translational chemistry

Cutting-edge technologies meet traditional paradigms in assay development

The Future Of Drug Discovery - Cutting-edge technologies meet traditional paradigms in assay development By Dr Roger Bosse With more than 1,500 drugs approved by the Food and Drug Administration (FDA) on the market, the easiest disease targets are already covered (1). Today’s scientists are challenged to find new compounds,… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Bioengineering #Business #Cell / tissue culture #Cell culture #Cellular assays #Chemical engineering #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Genetics / genomes #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Oncology #Precision medicine #Preclinical #Regenerative Medicine #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Toxicology #Translational #Translational chemistry

Induced Pluripotent Stem Cells (iPSCs) – Unlocking their full potential

Induced Pluripotent Stem Cells (iPSCs) - Unlocking their full potential for Drug Discovery By Abby Edwards and Dr Richard Massey Human stem cells were once viewed primarily as regenerative materials for tissue repair through cell therapies. However, advances in technologies and protocols mean that induced pluripotent stem cells (iPSCs) are… Read More

#Archive